Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
News|Articles|June 1, 2002
- Pharmaceutical Technology-06-02-2002
- Volume 26
- Issue 6
Screening for Counterfeit Drugs Using Near-Infrared Spectroscopy
Author(s)Bernard A. Olsen, PhD
Near-infrared spectroscopy is a sophisticated and selective technique that has emerged as a powerful tool for the analysis of pharmaceuticals.
Advertisement
Articles in this issue
over 24 years ago
Excipient GMP Quality Standards: One is Enoughover 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Technology Advances Anticounterfeiting Optionsover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Building on Tradition: Integrating the Links of ExpertiseAdvertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement